为了获得访问"阿拉丁铁蛋"实时聊天框的流畅支持体验,建议您使用Chrome浏览器或选择360浏览器极速模式(如何切换极速模式?),感谢您选择我们!

Barasertib (AZD1152-HQPA),Aurora B激酶抑制剂

高效的选择性Aurora B激酶抑制剂
规格或纯度: ≥97%
有货

库存信息

关闭

库存信息

关闭

库存信息

关闭
货号 (SKU) 包装规格 是否现货 价格 数量
A127799-10mg
10mg 现货 Stock Image
A127799-50mg
50mg 现货 Stock Image
A127799-250mg
250mg 现货 Stock Image
查看相关系列
aurora kinase B Inhibitor

基本描述

英文别名 722544-51-6|AZD1152-HQPA|barasertib-hQPA|AZD-1152HQPA|Barasertib (AZD1152-HQPA)|defosbarasertib|2-(3-((7-(3-(ethyl(2-hydroxyethyl)amino)propoxy)quinazolin-4-yl)amino)-1H-pyrazol-5-yl)-N-(3-fluorophenyl)acetamide|UNII-29P8LWS24N|AZD-1152-HQPA|INH 34|INH-34
规格或纯度 ≥97%
英文名称 Barasertib (AZD1152-HQPA)
生化机理 AZD1152-HQPA is the active metabolite of AZD-1152, a potent selective Aurora Kinase B inhibitor. AZD1152 is 50-fold selective for Aurora kinase B over Aurora kinase C and over 1000-fold selective for Aurora kinase B over Aurora Kinase A. (IC50s: aurora-A, 1,369 nmol/L; aurora-B, 0.36 nmol/L; aurora-C, 17.0 nmol/L). It is converted in plasma to the active form AZD1152-HQPA, which has been shown to have antineoplastic activity in a variety of animal models and human cancer cell lines. .Potent, selective Aurora B kinase inhibitor (IC 50 = 0.37 nM). Induces apoptosis in vitro . Antitumor agent. Cell-permeable. Active in vitro and in vivo .
储存温度 -20°C储存
运输条件 超低温冰袋运输
备注 如果有可能,您尽量在使用的当天配置溶液,并在当天使用完它。但是,如果您需要预先配制储备溶液,我们建议您将溶液等份保存在-20°C的密封小瓶中。通常,它们最多可以使用一个月。在使用前和打开样品瓶之前,我们建议您让您的产品在室温下平衡至少1小时。需要更多关于溶解度,用法和处理的建议吗?请访问我们的常见问题(FAQ)页面以获取更多详细信息。
产品介绍

AZD1152-HQPA是AZD-1152的活性代谢物,AZD1152-HQPA (Barasertib)是Aurora B 高选择性抑制剂,IC50为0.37 nM,比对Aurora A的抑制性高100倍。A highly selective ARK-2 inhibitor

AZD1152-HQPA is the active metabolite of AZD-1152, AZD1152-HQPA (Barasertib) is a highly selective Aurora B inhibitor with IC50 of 0.37 nM, ~100 fold more selective for Aurora B over Aurora A.
A highly selective ARK-2 inhibitor

名称和标识符

IUPAC Name 2-[3-[[7-[3-[ethyl(2-hydroxyethyl)amino]propoxy]quinazolin-4-yl]amino]-1H-pyrazol-5-yl]-N-(3-fluorophenyl)acetamide
INCHI InChI=1S/C26H30FN7O3/c1-2-34(10-11-35)9-4-12-37-21-7-8-22-23(16-21)28-17-29-26(22)31-24-14-20(32-33-24)15-25(36)30-19-6-3-5-18(27)13-19/h3,5-8,13-14,16-17,35H,2,4,9-12,15H2,1H3,(H,30,36)(H2,28,29,31,32,33)
InChi Key QYZOGCMHVIGURT-UHFFFAOYSA-N
Canonical SMILES CCN(CCCOC1=CC2=C(C=C1)C(=NC=N2)NC3=NNC(=C3)CC(=O)NC4=CC(=CC=C4)F)CCO
Isomeric SMILES CCN(CCCOC1=CC2=C(C=C1)C(=NC=N2)NC3=NNC(=C3)CC(=O)NC4=CC(=CC=C4)F)CCO
WGK Germany 3
PubChem CID 16007391
分子量 507.56

化学和物理性质

溶解性 DMSO ≥100mg/mL Water ≥100mg/mL Ethanol ≥2.8mg/mL
折光率 1.68
沸点 796.7° C at 760 mmHg

安全和危险性(GHS)

WGK Germany 3

质检证书(COA)

质检报告(COA)

输入批号以搜索COA:

相关文档

质检报告COA

请输入批号:


产品问答

产品问答

登录提交问题 Hover me 请先登录再提交问题
您提交该产品问题后,我们会在1-2个工作日内给您答复,您可以登录"我的账号",然后点击"我的产品问答"查看答案

参考文献

1. Mortlock AA, Foote KM, Heron NM, Jung FH, Pasquet G, Lohmann JJ, Warin N, Renaud F, De Savi C, Roberts NJ et al..  (2007)  Discovery, synthesis, and in vivo activity of a new class of pyrazoloquinazolines as selective inhibitors of aurora B kinase..  J Med Chem,  50  (9):  (2213-24).  [PMID:17373783]
2. Schwartz GK, Carvajal RD, Midgley R, Rodig SJ, Stockman PK, Ataman O, Wilson D, Das S, Shapiro GI.  (2013)  Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors..  Invest New Drugs,  31  (2):  (370-80).  [PMID:22661287]
3. Floc'h N, Ashton S, Taylor P, Trueman D, Harris E, Odedra R, Maratea K, Derbyshire N, Caddy J, Jacobs VN et al..  (2017)  Optimizing Therapeutic Effect of Aurora B Inhibition in Acute Myeloid Leukemia with AZD2811 Nanoparticles..  Mol Cancer Ther,  16  (6):  (1031-1040).  [PMID:28292940]
4. Mitchell E et al..  (2020)  XMU-MP-1 induces growth arrest in a model human mini-organ and antagonises cell cycle-dependent paclitaxel cytotoxicity..  Cell Div,  15  ():  (11).  [PMID:32973917]